The US Food and Drug Administration (FDA) approved Leo Pharma’s great growth hope, tralokinumab, shortly before the New Year. Leo Pharma is now beginning to roll out the drug in the US.
This hasn’t stopped the pharmaceutical company from developing the treatment further, including the way patients are treated with the drug. Leo Pharma has just registered a new phase III trial with tralokinumab administered as subcutaneous injection using something only described as ”device A.”
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Long wait for IVDR implementation is over, putting an end to pandemic "wild west"
After prolonged debates on potential bottlenecking and supply issues, the EU’s long-awaited In Vitro Diagnostic Medical Devices Regulation comes into force on May 26.
GN purchase story is very speculative, says analyst
Competition rules could block a purchase of GN Store Nord and subsequent divestment of GN Hearing, says a Sydbank analyst on the speculative story that this might be underway.
Bavarian Nordic upgrades guidance following vaccine contract
Bavarian has been the center of attention in recent days due to its monkeypox vaccine, and the company has now secured a vaccine contract with another undisclosed country. Consequently, Bavarian has raised its expectations for the full year.
Novo Nordisk invests additional millions of dollars in new manufacturing facilities
Novo Nordisk’s DKK 17bn (USD 2.4bn) investment into upgrading and building new facilities in Kalundborg last year has now been followed by a DKK 1bn (USD 143.8m) investment in the same location.
US to start using Bavarian vaccine stockpile
In an attempt to contain a monkeypox outbreak, US authorities will start offering certain people Bavarian Nordic-developed Jynneos vaccinations against the infectious disease.
Production Director 
2 Sales Representatives and Product Specialists 
Key Account Manager, Europe and Asia 
Industrial Designer- Design Engineer 
Director for innovative pre-clinical testing unit 
System Sales Development Consultant - Investment Projects, Merck Millipore 
Director of Toxicology 
Director Global Engineering 
Clinical Project Manager 
Senior Manager, Clinical Trial Budget 
KLIFO is looking for a Clinical Supply Manager for our Glostrup office 
Laboratory technician for process development and clinical manufacturing 
Analytical Coordinator for Analytical Development 
Nordic Medical Affairs Manager 
Account Manager 
(Senior) Drug Substance Specialist 
Client Talent Acquisition Specialist 
Senior Project Manager (GMP - Life Science) 
Communications Consultant